» Articles » PMID: 23687091

FLT3 Inhibitor-induced Neutrophilic Dermatosis

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2013 May 21
PMID 23687091
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The FLT3-ITD mutation is associated with poor outcomes in acute myeloid leukemia. Multiple FMS-like tyrosine kinase 3 (FLT3)-inhibitors have been studied in clinical trials. Recently, potent FLT3 inhibition was shown to induce terminal differentiation of FLT3-mutant myeloblasts. In 3 patients who developed characteristic skin nodules on initiation of FLT3-inhibition, we conducted dermatopathologic evaluation of skin samples, as well as FLT3 and NPM1 mutational analysis and fluorescence in situ hybridization. All 3 patients demonstrated characteristically deep dermal and subcutaneous neutrophilic infiltrates without evidence of myeloblasts. Discovery of FLT3-ITD and NPM1 mutations in 2 of the samples, as well as the presence of FLT3-ITD and deletion of 7q in the other, confirmed the ancestry of the differentiated neutrophils as that of the original FLT3-mutant myeloblasts. FLT3 inhibition can lead to clinically distinct dermatoses, which suggests the effect of FLT3 inhibition on myeloid differentiation and a manifestation of a broader "syndrome" associated with this therapy.

Citing Articles

Unveiling unexpected adverse events: post-marketing safety surveillance of gilteritinib and midostaurin from the FDA Adverse Event Reporting database.

Jiang T, Li Y, Zhang N, Gan L, Su H, Xiang G Ther Adv Drug Saf. 2025; 16():20420986241308089.

PMID: 39802043 PMC: 11724423. DOI: 10.1177/20420986241308089.


Sweet's syndrome associated with FLT3 inhibition.

Seervai R, Paz Munoz E, Freeman S, Swords R, White K, Keller J JAAD Case Rep. 2024; 54:89-92.

PMID: 39687070 PMC: 11646748. DOI: 10.1016/j.jdcr.2024.09.013.


Acute Febrile Neutrophilic Dermatosis (Sweet Syndrome) in Acute Myeloid Leukemia Patients: A 28-Year Institutional Experience.

Cowen E, Barrios D, Pulitzer M, Moy A, Dusza S, De Wolf S Acta Haematol. 2023; 147(4):457-464.

PMID: 37989105 PMC: 11740260. DOI: 10.1159/000535399.


AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens.

Milnerowicz S, Maszewska J, Skowera P, Stelmach M, Lejman M Int J Mol Sci. 2023; 24(21).

PMID: 37958832 PMC: 10647248. DOI: 10.3390/ijms242115849.


Protective effect of borneol on the cutaneous toxicity of gilteritinib.

Zhou Y, Yin Y, Huang X, Hu Y, He Q Zhejiang Da Xue Xue Bao Yi Xue Ban. 2023; 52(5):544-557.

PMID: 37899395 PMC: 10630053. DOI: 10.3724/zdxbyxb-2023-0261.